Sign in
CompletedNo phase

Exploratory Study of SAT-001 in Treatment of Pediatric Patient With Myopia

Key facts

Who runs it
S-Alpha Therapeutics, Inc.
Where
South Korea6 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
60 people enrolled
Started
5 Mar 2021
Ended
3 Apr 2024
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • SAT-001(Software as Medical Device)
Record updated
3 May 2024

Who can take part

Age
5 years to 12 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Pediatric patient age 5 to 12 years old at the Screening Visit
  • Diagnosed with myopia as following refractive error via cycloplegic refraction(CR); Spherical equivalent (SE) -0.75 D or more and less than -6.00 D in each eye; Astigmatism of 1.50 D or less in each eye; Anisometropia of less than 1.00 D
  • The age of birth over 38 weeks
  • Over 2500g of birth weight
  • Best corrected distance visual acuity of 0.2 logMAR or better in each eye at the Screening Visit
  • Intraocular pressure 21 mmHg or less in each eye at the Screening Visit

Who cannot take part

  • Administration of anti-muscarine drugs within 1 month before screening visit
  • Current or previous use of multi-focal lenses
  • History of atropine use for treatment of myopia within 1 month before screening visit
  • Participation in another clinical trial within 6 months before screening visit
  • History of growth hormone treatment within 1 month before screening visit
  • Currently taking or having taken antihistamines (tablets, nasal spray, eye drops, etc.) or psychiatric drugs (antidepressants, anti-anxiety medications, etc.) within 30 days before screening visit
  • History of injections with histamine release and cholinergic effect within 30 days before screening visit
  • Abnormal conditions in cornea, lens, central retina, iris and ciliary bodies or malignant tumors around orbit
  • History of manifest strabismus, intermittent strabismus, amblyopia, nystagmus etc. (except for phoria maintaining binocular vision)
  • History of ophthalmic surgery, such as eyelid surgery, strabismus surgery, intraocular surgery, or refractive correction surgery (except for epiblepharon surgery)
  • Obsessive-compulsive disorder or attention deficit hyperactivity disorder(ADHD)
  • Down's syndrome or cerebral palsy
  • Significant systemic diseases such as congenital heart disease, respiratory system disease (except for asthma), endocrine disease or nervous system disease
  • Planning to use or having used Orthokeratology lenses (Ortho-K lenses), Rigid Gas Permeable (RGP) lenses, and other contact lenses to reduce the progression of myopia
  • Medically clear to have abnormal range of intellectual development
  • Incongruent to participate in this study at the discretion of the investigator

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The Purpose of this study is to explore the safety and effectiveness of SAT-001, a medical device for the treatment of myopia in pediatric patient with myopia

The 2 groups in the trial

  • SAT-001Treatment being tested

    Treatment: SAT-001(Software as Medical Device)

  • Control GroupNo study treatment, for comparison

    Wearing glasses or not

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomised, Open-label, Multicenter, Controlled, Exploratory Study on the Effect and Safety of SAT-001 as a Medical Device in Treatment of Pediatric Patients With Myopia
Record updated
3 May 2024